Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-04-23

Clinical Trial Update: The Effect of Naltrexone and Varenicline on Alcohol-Mediated Smoking Lapse [Phase 2]

View source ↗

Summary

Phase 2 study evaluating whether naltrexone and varenicline together reduce alcohol-triggered smoking lapses in smokers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Naltrexone (Naltrexone)
  • Varenicline (varenicline)

Snippet

Sponsor: Yale University | Conditions: Smoking | Phase 2 | Status: COMPLETED | Results posted: 2018-04-23